The aim of this study is to see how safe and effective linvoseltamab is compared to a combination of three cancer drugs: elotuzumab, pomalidomide and dexamethasone, (called EPd) in participants who have returned after having received prior treatment that included lenalidomide, a proteasome inhibitor, and (for participants in some countries) a cluster of differentiation 38 (CD38) antibody.
This trial is currently open and accepting patients.
This clinical trial is seeking approximately 380 participants. This is a Phase 3 trial that is randomized and open-label. Randomized means that the treatment each participant receives will be randomly assigned by a computer program. Open-label means that both the participants and the trial doctors will know what treatment the participants are receiving. Participants will be screened up to 28 days before the trial and then participate in the trial for as long as they are receiving benefit or until they leave the trial for another reason.
The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.
Phase 3
Enrollment: 380 patients (estimated)
View MoreView all clinical trial locations sorted by state.
Charlotte, NC
Seattle, WA
We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.
(888) 828-2206If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.
Find Nearby LocationsYou can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message
Learn more about how we work with trial sponsors